Simulations Plus, Inc. (NASDAQ: SLP) recently announced significant changes to its business unit and leadership structure, effective August 30, 2024, following the company's recent strategic acquisitions. These changes are aimed at optimizing the company's operations to support future growth opportunities.
One of the key highlights is the formation of two new business units – Adaptive Learning & Insights and Medical Communications – alongside the transformation of the Regulatory Strategies business unit into a new Regulatory Strategies Center of Excellence. These changes are expected to enhance customer engagement and visibility within the sales organization, consequently accelerating cross-selling opportunities.
The company also revealed several leadership promotions and transitions:
- Steven Chang, who joined Simulations Plus in June 2023, will be promoted to President, Quantitative Systems Pharmacology.
- Jenna Rouse, who joined the company with the acquisition of Pro-ficiency, will be promoted to President of the newly formed Adaptive Learning & Insights business unit.
- Murry Alper, also from the Pro-ficiency acquisition, will be promoted to President of the newly formed Medical Communications business unit.
- Sandra Suarez-Sharp, Ph.D., who joined the company in 2020, will transition to President, Regulatory Strategies Center of Excellence.
Simulations Plus also announced the departure of Brett Howell, Ph.D., President, Quantitative Systems Pharmacology, and Michael Raymer, President, Clinical Simulations & Medical Communications, following their assistance with the transition process.
The company emphasized its excitement about the potential to create long-term value for stakeholders, highlighting its suite of end-to-end and innovative offerings that span the drug development continuum, positioning Simulations Plus in a unique competitive position to scale the business for growth and profitability.
Simulations Plus, with over 25 years of experience, offers advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company's comprehensive biosimulation solutions integrate artificial intelligence/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches, and are used by leading pharmaceutical, biotechnology, and regulatory agencies globally. As a result of these announcements, the company's shares have moved 0.7% on the market, and are now trading at a price of $36.73. Check out the company's full 8-K submission here.
